Lilly
Executive Summary
Licenses Cytogen's proprietary monoclonal antibody-based technology for the site-specific delivery of vinca alkaloid compounds and other cancer therapies patented by Lilly in return for an unspecified licensing fee, an equity investment and royalty payments. Lilly will be responsible for clinicals and seeking FDA approval. Firms have completed animal testing of possible product formulations. Agreement will complement monoclonal antibody research activities at Lilly's Hybritech subsidiary.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.